Metactive Debuts Novel Embolization Technology

Human Health published Sun, 2014-03-23 10:03

Metactive Medical, Inc., an early-stage company focused on developing endovascular embolization devices for the treatment of neurovascular and peripheral vascular diseases, today presented new nonclinical data on one of its investigational devices at the Society of Interventional Radiology's (SIR) Annual Scientific Meeting. Metactive currently has two devices under development, and today's presentation focused on the company's device that addresses the cerebral aneurysm market. The company's chief executive officer, F. Nicholas Franano, MD, made an oral presentation entitled "Over-the-wire Device for Immediate, Complete and Durable Occlusion of Saccular Cerebral Aneurysms" during the "Arterial Aneurysms and Dissection" session at the meeting.
 

 

"Endovascular embolization of cerebral aneurysms with coils was a major advance when it was introduced more than 20 years ago," said Dr. Franano. "The technology that we are developing at Metactive builds upon that innovation by providing a next-generation device that has the potential to provide better patient outcomes, to be faster and easier for physicians to use, and to improve hospital profitability."
 

 

Physicians treat approximately 280,000 aneurysms per year worldwide using surgical clips, endovascular coils and flow-diverting stents. Current treatments are complex and costly, and do not consistently result in complete and permanent occlusion of aneurysms. At SIR today, Metactive presented findings from a recent pilot nonclinical study in which the company's cerebral aneurysm embolic device demonstrated immediate and complete mechanical occlusion of a large, terminal saccular aneurysm, as well as full endothelialization and sealing of the aneurysm neck at one month. By comparison, in the same aneurysm model, treatment using widely used conventional coils did not provide immediate and complete occlusion. Compared to coiling, the procedure to place Metactive's device took half as long, and the devices cost one-third as much. While Metactive has only completed a handful of nonclinical procedures to date, these excellent early results support further investigation.
 

 

"If Metactive can demonstrate that this new device can provide better clinical outcomes with much lower procedure time and complexity, and large reductions in cost, then I believe it has the potential to provide real value for patients, physicians, hospitals and payers -- especially for large aneurysms," said Kieran Murphy, MD, interventional neuroradiologist and professor of radiology at the University Health Network Toronto in Ontario, Canada, and director of clinical faculty at the Techna Research Institute.
 

Share

Terratek® Flex, the Market’s First Compostable Elastomeric Bioplastic

Agribusiness published Wed, 2014-03-12 10:43

Terratek® Flex, the market’s first compostable elastomeric bioplastic, can be used as an impact modifier for polylactic acid (PLA), increasing impact strength, elongation and flexibility without sacrificing compostability.

Green Dot’s Product Development Manager, Mike Parker, will present his findings on the efficacy of Terratek® Flex as an impact modifier for PLA at the the Global Plastics Environmental Conference (GPEC) in Orlando, Florida on March 13, 2014. Mr. Parker analyzed the physical properties of PLA modified with Terratek® Flex over a range of loading ratios. He will discus how levels of Terratek® Flex can be customized to achieve desired cost and performance.

Terratek® Flex is the market’s first elastomeric bioplastic to be certified to meet U.S. (ASTM D6400) and E.U. (EN 13432) standards for compostability. The rubber-like material is strong, durable and pliable. It has been tested by NSF International laboratories to be free from phthalates, bisphenol A, lead and cadmium. When compounded with PLA, Terratek® Flex can enhance physical properties, increasing impact strength, elongation and flexibility without sacrificing compostability.

GPEC is presented by the Society of Plastics Engineers’ (SPE) Plastic Environmental Division (PED). The conference focuses on the unique blend of recycling, reclamation and bioplastics.  

About Green Dot Holdings LLC - Green Dot is a bioscience social enterprise headquartered in Cottonwood Falls, Kansas. The company serves the plastics industry and style conscious consumers with a full line of biobased and compostable materials sold under the Terratek® brand name. Green Dot aspires to improve the environment in which we live by building a more sustainable world with renewable biobased resins and promoting their use through invention, creation and research. Learn more at www.GreenDotPure.com.

Share

Health Outcomes Sciences Completes First Close of Series A Preferred Financing

Human Health published Wed, 2014-03-05 22:09

Kansas Bioscience Authority, Grayhawk Venture Fund II Lead Round

Health Outcomes Sciences Inc. (HOS), a leading health care IT company based in Overland Park, Kan., today announced that it has completed the first close of its Series A Preferred financing round. The company has raised $5 million in the first closing and expects to raise up to an additional $2 million of capital, bringing the round to $7 million.

The round, which is led by the Kansas Bioscience Authority (KBA) and Grayhawk Venture Fund II (GVFII), also includes a broad representation of existing angel investors. The funds will be used to grow sales of the company’s ePRISM® clinical decision support software, which provides evidence-based individualized risk models to physicians where they need them most, at the point of care.   

“We are thrilled to have KBA and Grayhawk join us in our pursuit to impact the cost-quality paradox in health care,” said Matt Wilson, HOS president and CEO. “HOS is among the first to capitalize on a huge market for technologies capable of personalizing patient analytics and applying them in direct clinical care. This round of funding will help us build on our early success in cardiology and extend our reach to other specialties.”

Keith Harrington, KBA managing director, said, “KBA is delighted to partner with the Health Outcomes Sciences team to accelerate the company’s sales growth and improve patient outcomes. This is a great example of a Kansas-based, world-class life sciences company doing important work throughout the U.S.”  

Brian Burns, GVFII partner, added, “HOS is at the leading edge of using big data for supporting medical decisions. We are excited to be a part of a company that can improve both health outcomes and cost containment in hospitals.”

Share